Scarica l'app Stockscreener
16.30
2.57%
-0.43
Enliven Therapeutics Inc Borsa (ELVN) Ultime notizie
Enliven Therapeutics CSO sells $84k in shares By Investing.com - Investing.com Nigeria
Enliven Therapeutics (NASDAQ:ELVN) Insider Joseph Lyssikatos Sells 5,000 Shares of Stock - MarketBeat
Enliven Therapeutics CSO sells $84k in shares - Investing.com
Enliven Therapeutics (NASDAQ:ELVN) Stock Price Down 6.1%Here's What Happened - MarketBeat
First Week of February 2026 Options Trading For Enliven Therapeutics (ELVN) - Nasdaq
Portfolio Shifts: Is Enliven Therapeutics Inc. stock near bottom after decline2025 Volatility Report & Daily Entry Point Trade Alerts - moha.gov.vn
Will Enliven Therapeutics Inc. stock benefit from AI adoption2025 Top Decliners & Fast Exit/Entry Strategy Plans - Улправда
Is Enliven Therapeutics Inc. stock near bottom after declineFed Meeting & Free Weekly Watchlist of Top Performers - Улправда
Technical Reactions to ELVN Trends in Macro Strategies - Stock Traders Daily
What risks investors should watch in Enliven Therapeutics Inc. stockJuly 2025 Technicals & Weekly Chart Analysis and Trade Guides - DonanımHaber
Is Enliven Therapeutics Inc. stock a buy before product launchesJuly 2025 Volume & Verified Stock Trade Ideas - DonanımHaber
How Enliven Therapeutics Inc. stock reacts to oil prices2025 Top Gainers & Long-Term Investment Growth Plans - DonanımHaber
How resilient is Enliven Therapeutics Inc. stock in market downturnsWeekly Trend Report & Low Volatility Stock Suggestions - DonanımHaber
Will Enliven Therapeutics Inc. stock gain from strong economy2025 Biggest Moves & Real-Time Buy Zone Alerts - Улправда
Enliven Therapeutics (ELVN) Stock Analysis Report | Financials & Insights - Benzinga
Enliven Therapeutics (NASDAQ: ELVN) registers shares for 2025 equity inducement plan - Stock Titan
Enliven Therapeutics, Inc.Common Stock (NQ: ELVN - Markets Financial Content
VIX Spike: How resilient is Enliven Therapeutics Inc stock in market downturnsQuarterly Trade Report & Risk Managed Investment Signals - moha.gov.vn
Enliven Therapeutics Earnings Notes - Trefis
5AM Venture Management LLC Reduces Stock Holdings in Enliven Therapeutics, Inc. $ELVN - Defense World
CEO moves at Prolynx, Centessa, Kyowa Kirin, Enliven, Expression - BioCentury
Enliven Therapeutics (ELVN) officer-director discloses no owned securities - Stock Titan
Enliven Therapeutics Appoints Richard Fair as CEO - The Globe and Mail
Enliven Therapeutics (NASDAQ:ELVN) COO Anish Patel Sells 6,663 Shares of Stock - MarketBeat
Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules - Nasdaq
Enliven Therapeutics (NASDAQ:ELVN) Shares Down 6.5% Following Insider Selling - MarketBeat
Enliven Therapeutics appoints Rick Fair as new CEO - Investing.com
Enliven Therapeutics, Inc. Announces Management Changes - marketscreener.com
Enliven Therapeutics appoints Rick Fair as new CEO, shares down - TradingView — Track All Markets
Enliven Therapeutics Appoints Rick Fair as CEO - marketscreener.com
Enliven Therapeutics appoints Rick Fair as new CEO By Investing.com - Investing.com South Africa
Enliven Therapeutics Appoints New CEO and Director - TradingView — Track All Markets
[8-K] Enliven Therapeutics, Inc. Reports Material Event | ELVN SEC FilingForm 8-K - Stock Titan
Enliven Therapeutics announces new CEO to drive next phase of development - marketscreener.com
Enliven Therapeutics Announces New CEO to Drive Next Phase of Development - PR Newswire
COO Patel Sells 6,663 ($140.1K) Of Enliven Therapeutics Inc [ELVN] - TradingView — Track All Markets
Top investors say Enliven Therapeutics Inc (ELVN) ticks everything they need - setenews.com
Enliven Therapeutics (NASDAQ:ELVN) Sees Unusually-High Trading VolumeHere's What Happened - MarketBeat
Enliven Therapeutics (ELVN): Evaluating Valuation After a Recent Share Price Rebound and Ongoing Clinical Progress - Yahoo Finance
Tiny Biotech Terns Takes Aim At Novartis' Leukemia Blockbuster - Benzinga
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Enliven Therapeutics: ENABLE trial shows promise in treating atypical fusion CML - Traders Union
Trading the Move, Not the Narrative: (ELVN) Edition - news.stocktradersdaily.com
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Will Enliven Therapeutics Inc stock benefit from AI adoptionJuly 2025 Setups & Long-Term Capital Growth Strategies - moha.gov.vn
Affinity Asset Advisors LLC Buys Shares of 400,000 Enliven Therapeutics, Inc. $ELVN - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) and PreveCeutical Medical (OTCMKTS:PRVCF) Head-To-Head Analysis - Defense World
Can Enliven Therapeutics Inc. stock deliver surprise earnings beatTrade Analysis Report & Free Low Drawdown Momentum Trade Ideas - Newser
Enliven Therapeutics (ELVN): Assessing Valuation After a Recent 13% Share Price Rebound - Sahm
Wall Street Analysts Believe Enliven Therapeutics, Inc. (ELVN) Could Rally 101.26%: Here's is How to Trade - sharewise.com
Ready to Jump After Recent Trade: Enliven Therapeutics Inc (ELVN) - setenews.com
Will Enliven Therapeutics Inc. stock keep outperforming rivals2025 Price Targets & Long-Term Capital Growth Strategies - Newser
Is Enliven Therapeutics Inc. stock ready for breakout2025 Volume Leaders & Long-Term Growth Stock Strategies - Newser
Enliven Therapeutics (NASDAQ:ELVN) Shares Down 8%Time to Sell? - MarketBeat
0.08%
0.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):